arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Prime Medicine, Inc.

PRME Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$3.48
▼ -8.5% Today
as of Oct 23, 11:20 ET
Last 30 days +8.65% Sep 14 → Oct 23
$2.79 $3.11 $3.43 $3.76 $4.08 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$3.67
High
$3.92
Low
$3.62
Volume
$5M
Avg Vol
$3M
Mkt Cap
$707M
P/E (TTM)
—
Beta
—
52w High
$5.55
52w Low
$2.67
Div Yield
—
Shares Out
$181M

Recent Press Releases & News last 60 days · 9 items

Oct 12 · 15:24 Zacks
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why
Oct 5 · 13:14 MT Newswires
Prime Medicine Doses First Patient in Trial of Investigational Wilson Disease Treatment
Oct 5 · 12:00 PR GlobeNewswire
Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
▸ Show all 9 press releases & news Free account →

PRME earnings at a glance

Prime Medicine, Inc. (PRME) is scheduled to report earnings on Friday, November 6, 2026 — in 14 days. Analysts expect earnings per share of -$0.23, compared with -$0.32 in the same quarter last year (+28%). The options market is pricing a move of about ±19.2% after the report, a range of roughly $2.81 to $4.15 from today's $3.48. Over its last 6 reports the stock rose the next day 0 times and fell 6, moving ±7.9% on average; after the most recent report on Aug 6, 2026 it moved -4.2%. That means options currently expect more movement than PRME has typically delivered. PRME beat the consensus EPS estimate in 1 of its last 6 reported quarters. Implied volatility is currently 162%. The share price of $3.48 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$2.67
$5.55
28% of range
Avg surprise (last 6)
-9.6%
Avg reaction (last 6)
-7.9%
0% positive
Latest IV / EM
162%
EM ±19.2% · $4 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.55$-0.47$-0.39$-0.30$-0.22 Actual $-0.44Actual $-0.47Actual $-0.55Actual $-0.44Actual $-0.46Actual $-0.44Actual $-0.40Est $-0.32Actual $-0.41Est $-0.36Actual $-0.32Est $-0.28Actual $-0.22Est $-0.25Actual $-0.28Est $-0.24Actual $-0.24Est $-0.24 MarJunSepMarJunSepMar/2025Jun/2025Sep/20258KMar/2026Jun/2026
Revenue vs Net Income Revenue Net income
$-53M$-39M$-26M$-12M$2M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Thu Aug 6, 2026Jun/2026 $-0.24 $-0.24 0.0% +41.5% -4.2% earnings
Thu May 7, 2026Mar/2026 $-0.28 $-0.24 -16.7% +30.0% -8.7% earnings
Tue Mar 3, 20268K 2026-03-03 $-0.22 $-0.25 +12.0% — -9.2% earnings
Fri Nov 7, 2025Sep/2025 $-0.32 $-0.28 -14.3% — -8.9% earnings
Thu Aug 7, 2025Jun/2025 $-0.41 $-0.36 -13.9% — -9.6% earnings
Thu May 8, 2025Mar/2025 $-0.40 $-0.32 -25.0% — -7.0% earnings
Mon Sep 30, 2024Sep 2024 $-0.44 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.46 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.44 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.55 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.47 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.44 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Fri Nov 6, 2026Sep/2026OTHER -$0.23-$0.32 +28.1%

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue———$1M$1M$1M—$209,000
Cost of revenue————————
Gross profit————————
Operating income$-43M$-51M—$-54M$-53M$-52M—$-54M
Net income$-42M$-49M—$-51M$-53M$-52M—$-53M
EPS (diluted)$-0.24$-0.28—$-0.32$-0.41$-0.40—$-0.44

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$47M$64M$63M$71M$54M$92M$182M$118M
Inventory————————
Total current assets$97M$138M$181M$231M$121M$164M$212M$246M
Total assets$249M$295M$343M$385M$279M$328M$298M$333M
Long-term debt————————
Total liabilities$209M$218M$222M$223M$218M$221M$144M$143M
Total equity$40M$77M$121M$162M$61M$107M$153M$190M

Implied volatility — last 90 days

31%191%351%511%671% Jun 09 — IV 125% · EM ±15.6%Jun 10 — IV 185% · EM ±21.9%Jun 11 — IV 160% · EM ±17.7%Jun 12 — IV 176% · EM ±18.0%Jun 15 — IV 152% · EM ±11.0%Jun 16 — IV 290% · EM ±17.1%Jun 19 — IV 119% · EM ±26.3%Jun 22 — IV 99% · EM ±20.8%Jun 23 — IV 117% · EM ±23.9%Jun 24 — IV 72% · EM ±14.4%Jun 25 — IV 62% · EM ±12.2%Jun 26 — IV 53% · EM ±10.2%Jun 29 — IV 110% · EM ±19.5%Jun 30 — IV 102% · EM ±17.6%Jul 01 — IV 77% · EM ±12.9%Jul 02 — IV 173% · EM ±27.9%Jul 03 — IV 182% · EM ±28.4%Jul 06 — IV 95% · EM ±13.2%Jul 07 — IV 91% · EM ±12.0%Jul 08 — IV 149% · EM ±18.7%Jul 09 — IV 139% · EM ±16.4%Jul 10 — IV 108% · EM ±11.9%Jul 13 — IV 251% · EM ±20.9%Jul 15 — IV 581% · EM ±34.3%Jul 20 — IV 54% · EM ±12.8%Jul 21 — IV 69% · EM ±16.0%Jul 22 — IV 88% · EM ±20.2%Jul 23 — IV 84% · EM ±18.9%Jul 24 — IV 88% · EM ±19.6%Jul 27 — IV 99% · EM ±20.8%Jul 28 — IV 123% · EM ±25.1%Jul 29 — IV 91% · EM ±18.2%Jul 30 — IV 113% · EM ±22.1%Jul 31 — IV 125% · EM ±24.0%Aug 03 — IV 117% · EM ±20.7%Aug 04 — IV 93% · EM ±16.1%Aug 05 — IV 97% · EM ±16.2%Aug 06 — IV 84% · EM ±13.6%Aug 07 — IV 135% · EM ±21.1%Aug 10 — IV 143% · EM ±19.8%Aug 11 — IV 121% · EM ±16.0%Aug 12 — IV 143% · EM ±18.0%Aug 13 — IV 67% · EM ±7.9%Aug 14 — IV 73% · EM ±8.1%Aug 17 — IV 94% · EM ±7.9%Aug 18 — IV 89% · EM ±6.5%Aug 19 — IV 672% · EM ±39.7%Aug 20 — IV 406% · EM ±17.0%Aug 24 — IV 111% · EM ±23.1%Aug 25 — IV 158% · EM ±32.3%Aug 26 — IV 119% · EM ±23.7%Aug 27 — IV 100% · EM ±19.5%Aug 28 — IV 80% · EM ±15.2%Aug 31 — IV 31% · EM ±5.6%Sep 01 — IV 41% · EM ±7.0%Sep 02 — IV 122% · EM ±20.4%Sep 03 — IV 183% · EM ±29.6%Sep 04 — IV 125% · EM ±19.5%Sep 07 — IV 141% · EM ±19.6%Sep 08 — IV 43% · EM ±5.6%Sep 09 — IV 275% · EM ±34.5%Sep 16 — IV 480% · EM ±28.3%Sep 21 — IV 101% · EM ±21.2%Sep 22 — IV 93% · EM ±19.1%Sep 23 — IV 175% · EM ±35.1%Sep 24 — IV 109% · EM ±21.4%Sep 25 — IV 97% · EM ±18.6%Sep 28 — IV 98% · EM ±17.4%Sep 29 — IV 103% · EM ±17.8%Sep 30 — IV 137% · EM ±22.9%Oct 01 — IV 113% · EM ±18.2%Oct 02 — IV 97% · EM ±15.1%Oct 06 — IV 170% · EM ±22.4%Oct 07 — IV 118% · EM ±14.7%Oct 08 — IV 162% · EM ±19.2%

Sector peers

SLDB
Solid Biosciences Inc.
$734M $5.87-8.4%
DNA
Ginkgo Bioworks Holdings, Inc.
$738M $9.73-2.8%
FDMT
4D Molecular Therapeutics, Inc.
$765M $11.04-12.6%
VALN
Valneva SE
$647M $5.25-5.6%
CADL
Candel Therapeutics, Inc.
$777M $8.05-3.8%
AURA
Aura Biosciences, Inc.
$626M $6.25-3.2%

PRME earnings FAQ

When is PRME's next earnings date?

Prime Medicine, Inc. is expected to report on November 6, 2026.

What is PRME's expected move for earnings?

Options currently price a move of about ±19.2%, or $0.67 per share either way from $3.48.

How does PRME stock usually react to earnings?

Across the last 6 reports the average next-day move was ±7.9%, up 0 times and down 6 times.

What EPS are analysts expecting from Prime Medicine, Inc.?

The consensus estimate is -$0.23 per share, versus -$0.32 a year ago.

What is PRME's implied volatility?

PRME's at-the-money implied volatility is about 162% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in